Each patient in the European Union has a right of access to care. National governments face the challenge to balance resources against healthcare demand to ensure that populations enjoy equitable access to effective, affordable and sustainable healthcare. This study describes the main challenges with regard to access to affordable medicines, including Research & Development, pricing and reimbursement of medicines and the influence of the economic crisis. Potential policy options to tackle these challenges are presented, drawing on best practices and a review of specific measures implemented in different European countries. This document was provided by Policy Department A for the Committee on the Environment, Public Health and Food Safety.
Godman, B., Oortwijn, W., De Waure, C., Mosca, I., Puggina, A., Specchia, M. L., Campanella, P., Van Der Tuin, J., Links between Pharmaceutical R&D Models and Access to Affordable Medicines, European Parliament, Bruxelles 2016: 164 [http://hdl.handle.net/10807/93588]
Links between Pharmaceutical R&D Models and Access to Affordable Medicines
De Waure, Chiara;Puggina, Anna;Specchia, Maria Lucia;Campanella, PaoloPenultimo
;
2016
Abstract
Each patient in the European Union has a right of access to care. National governments face the challenge to balance resources against healthcare demand to ensure that populations enjoy equitable access to effective, affordable and sustainable healthcare. This study describes the main challenges with regard to access to affordable medicines, including Research & Development, pricing and reimbursement of medicines and the influence of the economic crisis. Potential policy options to tackle these challenges are presented, drawing on best practices and a review of specific measures implemented in different European countries. This document was provided by Policy Department A for the Committee on the Environment, Public Health and Food Safety.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.